United States · Venture startup

Who invested in SymbioCellTech

One round we have observed, with the 0 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Pharma

Funding summaryUpdated 26 Oct 2026

$200Kraised across 1 round since 2014, from 1 source

Latest round
Venture, $200KMar 2014
Investors
0
See who backed them

The rounds

  1. Mar 2014
    Venture$200K

    No investor was named in the report.

    From a historical funding recordSEC filing: $200K sold, first sale Mar 2014

Founders and team

From SymbioCellTech's own website and the SEC filings it signed: 10 on the team.

  • Travis ManningChief Operating Officer / Controller
  • Strategic AdvisorMeet Our Board →
  • Allen GardnerManager of LLCi
  • Anna GoochManager of LLCi
  • Axel ZanderManager of LLCi
  • Christof WestenfelderManager of LLCi
  • George ReissManager of LLCi
  • Phil HolmesManager of LLCi
  • Robert MaddockManager of LLCi
  • Susan McKeeverManager of LLCi

Also claim to have backed them

This firm lists SymbioCellTech as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.

Altitude LabAcceleratorPer its own site

Quick answers about SymbioCellTech

How much has SymbioCellTech raised?

SymbioCellTech has raised $200K across 1 round since 2014.

When did SymbioCellTech last raise?

SymbioCellTech's most recent round was a Venture of $200K in Mar 2014.

What was SymbioCellTech's biggest round?

Its most recent round, $200K in Mar 2014, is also its largest on record.

What stage is SymbioCellTech at?

SymbioCellTech's latest named round is a Venture, in Mar 2014.

Where is SymbioCellTech based?

SymbioCellTech is based in the United States.

Companies like SymbioCellTech

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.